Table 3.
Strategy | Comment |
---|---|
Type of malignancy, e.g., NSCLC, melanoma [83,84,85] * | Tend to have higher levels of immunogenicity |
Absence of lymphopenia and high neutrophil:lymphocyte ratios | Nonspecific indicators of poor antitumor immune responses |
Measurement of systemic immunosuppressive cytokines [83,96,97] | IL-1Ra, IL-2R, IL-10, and TGF-β1 are of particular significance in this context |
Measurement of tumor mutational load [86,87] | A high mutational load is predictive of good immunogenicity |
Computerized image analysis of tumor biopsies [108] | Enables immunological profiling of the tumor microenvironment |
Detection of the presence of PD-L1 and/or CD47 and MHC 1 on tumor cells [91,94,95] | Mab-targeting of these immunosuppressive proteins may promote immune eradication |
Specific epigenetic profiling (“EPIMMUN”) to predict responsiveness to PD-1-targeted MAbs in NSCLC [109] | Based on detection of the unmethylated status of the Treg transcription factor, Forkhead box P1 |
* Denotes the relevant references as cited in the text.